Three trials were enrolled, including one RCT [14] and two retrospective studies [13, 15] comparing the efficacy of antiplatelet regimens including P2Y12 inhibitors with other antiplatelet regimens excluding P2Y12 inhibitors in the prevention of new-onset migraine attacks following ASDC. The gene discussed is P2RY12; the disease is migraine disorder.